மைக்கேல் பேப் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
FYI Prague zakládá divizi pro lídry, povede ji Papežová
mediaguru.cz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mediaguru.cz Daily Mail and Mail on Sunday newspapers.
Want to Be an Entrepreneur? Take These Classes at UCF | University of Central Florida News
ucf.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ucf.edu Daily Mail and Mail on Sunday newspapers.
Markets
Needham analyst Chad Messer maintained a Buy rating on Esperion (ESPR – Research Report) today and set a price target of $134.00. The company’s shares closed last Tuesday at $26.88, close to its 52-week low of $23.90.
According to TipRanks.com, Messer is a 4-star analyst with an average return of 9.1% and a 47.8% success rate. Messer covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Phasebio Pharmaceuticals, and Aeglea Biotherapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Esperion with a $47.14 average price target, which is a 66.0% upside from current levels. In a report released yesterday, Credit Suisse also initiated coverage with a Buy rating on the stock with a $45.00 price target.